Group One Trading’s Atea Pharmaceuticals AVIR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-1,017,300
Closed -$2.95M 8115
2025
Q3
$2.95M Buy
+1,017,300
New +$3.47M 0.01% 1947
2025
Q2
Sell
-500
Closed -$1.5K 7925
2025
Q1
$1.5K Buy
500
+200
+67% +$624 ﹤0.01% 7087
2024
Q4
$1K Sell
300
-407,400
-100% -$1.35M ﹤0.01% 6885
2024
Q3
$1.37M Sell
407,700
-431,400
-51% -$1.56M ﹤0.01% 2043
2024
Q2
$2.78M Buy
839,100
+4,800
+0.6% +$17.9K 0.01% 1194
2024
Q1
$3.37M Buy
+834,300
New +$3.27M 0.01% 1106
2023
Q3
Sell
-600
Closed -$2.24K 7631
2023
Q2
$2.24K Buy
600
+100
+20% +$374 ﹤0.01% 7048
2023
Q1
$1.68K Buy
+500
New +$2.03K ﹤0.01% 6650
2022
Q4
Sell
-1,600
Closed -$9K 7212
2022
Q3
$9K Sell
1,600
-200
-11% -$1.53K ﹤0.01% 6539
2022
Q2
$13K Sell
1,800
-119,900
-99% -$819K ﹤0.01% 6590
2022
Q1
$879K Sell
121,700
-96,600
-44% -$656K ﹤0.01% 3216
2021
Q4
$1.95M Buy
218,300
+190,600
+688% +$2.97M ﹤0.01% 2626
2021
Q3
$971K Buy
27,700
+24,900
+889% +$691K ﹤0.01% 3446
2021
Q2
$60K Buy
+2,800
New +$84.1K ﹤0.01% 6419

Other funds holding AVIR

Group One Trading's AVIR Position: Q1 2026 in Review

Group One Trading reduced its Atea Pharmaceuticals (AVIR) stake by 100% in Q1 2026, selling an estimated $49.4K and leaving 30 shares worth $161. The position accounts for ﹤0.01% of the portfolio, ranked #7405.

Group One Trading first reported a position in AVIR in Q3 2021 and has held it in 12 quarters since. The position peaked at $1.32M in Q4 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Group One Trading held 30 shares of Atea Pharmaceuticals worth $161 as of Q1 2026.
  • Group One Trading sold 10,747 Atea Pharmaceuticals shares in Q1 2026, an estimated $49.4K.
  • Atea Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #7405 holding.
  • Group One Trading first reported a position in Atea Pharmaceuticals in Q3 2021 and has held it in 12 quarters since.
  • Group One Trading's Atea Pharmaceuticals position peaked at $1.32M in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.